Telehealth Weight Loss/GLP-1 Prescribing: What Prescribers Can Do in New York

If you’re a psychiatrist or PMHNP watching the GLP-1 revolution unfold, you’ve probably asked yourself: ‘Should I be prescribing these medications? Is it even within my scope?’

Here’s the reality: Yes, psychiatrists can prescribe weight-loss medications — and increasingly, it makes clinical sense to do so. But the regulatory landscape is complex, varying wildly by state, provider type, and prescribing method (especially telehealth).

This guide cuts through the confusion. We’ll cover what psychiatrists and PMHNPs need to know about prescribing GLP-1 agonists and other weight-loss drugs, the state-specific rules that matter, how scope of practice actually works, and what the economics look like in 2026.

Why Psychiatrists Are Getting Into Weight Management

Let’s start with the clinical case.

Your psychiatric patients are struggling with obesity. Many are dealing with medication-induced weight gain from antipsychotics or mood stabilizers. Others have co-occurring metabolic syndrome, binge eating, or depression that’s worsened by obesity. The connection between metabolic health and mental health isn’t new — but for years, we’ve treated them in separate silos.

That’s changing. GLP-1 medications like semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro, Zepbound) don’t just help patients lose weight. Early research suggests they may reduce cravings in substance use disorders, improve mood independent of weight loss, and lower systemic inflammation that affects brain health.

As Dr. Elliott Lewis, a board-certified psychiatrist and obesity medicine specialist, puts it: ‘If we truly understand that metabolic and mental health systems are inseparable, then psychiatrists being involved in metabolic treatment makes complete sense.’ You’re already monitoring metabolic side effects — glucose, lipids, weight gain. Prescribing a medication to actively address obesity isn’t a leap; it’s an extension of comprehensive care.

The key is doing it competently. That means understanding the medications, the regulations, and your state’s specific requirements.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Psychiatrists vs. PMHNPs: Who Can Prescribe What?

Psychiatrists (MD/DO): Full Prescriptive Authority

Psychiatrists have unrestricted prescribing authority in all 50 states for FDA-approved medications, including weight-loss drugs. Your medical license and DEA registration cover everything from phentermine (Schedule IV) to GLP-1 agonists like Wegovy (non-controlled).

That said, prescriptive authority doesn’t equal a free pass. You still need to:

• Follow state-specific clinical guidelines for obesity treatment (more on this below)
• Document proper indications (BMI ≥30, or ≥27 with comorbidities)
• Obtain informed consent and provide appropriate follow-up
• Stay within your clinical competency (consider additional training in obesity medicine)

The Scope Question: Some psychiatrists worry that prescribing for obesity falls outside their scope. The reality? Scope of practice is defined by competency, not tradition. If you’ve gained expertise through CME, mentorship, or formal certification (like the American Board of Obesity Medicine), you’re practicing within scope. Psychiatrists are already eligible for ABOM certification, which requires specialized education in metabolic physiology, nutrition, and anti-obesity pharmacotherapy.

PMHNPs: It Depends on Your State

For psychiatric nurse practitioners, prescribing weight-loss medications depends entirely on your state’s scope-of-practice laws.

Full Practice Authority States (~24 states): In states like Washington, Oregon, Colorado, and New Mexico, experienced PMHNPs can prescribe weight-loss medications independently after meeting state requirements (typically 3,000-4,000 hours of practice). You don’t need physician oversight, though you should still practice within your training and competency.

Reduced Practice States: States like New York, Pennsylvania, and Illinois require collaboration agreements with a physician, but experienced NPs can gain significant autonomy. For example:

• New York: After 3,600 hours of practice, NPs can work independently without a specific collaborating physician
• Illinois: NPs with ≥4,000 hours and ≥250 CE hours can obtain Full Practice Authority and prescribe independently, including controlled substances

Restricted Practice States: Texas, Florida, Alabama, and others require mandatory physician oversight for all NP prescribing. In these states:

• You must have a written Prescriptive Authority Agreement or Collaborative Protocol
• The supervising physician must be actively involved (chart reviews, availability for consult, regular meetings)
• Some states impose ratios (e.g., one Texas MD can supervise up to 7 NPs/PAs)

Even in full-practice states, practical barriers exist. Insurance companies and pharmacies sometimes require physician sign-off for high-cost GLP-1 prescriptions, even when not legally mandated. This is less about law and more about institutional gatekeeping around expensive medications.

Bottom line for PMHNPs: Check your state’s current regulations. If you need physician collaboration, that’s an added operational cost (typically $2,000-5,000/month for a collaborative physician service) — but it’s required for compliance.

State-Specific Rules You Must Know

Weight-loss prescribing isn’t just about having authority — it’s about following each state’s clinical requirements. Here are the critical rules in six major states:

Florida: Strict Documentation and Follow-Up

Florida’s Board of Medicine has detailed obesity prescribing rules (Florida Admin Code 64B15-14.004):

• BMI requirement: Patients must have BMI ≥30, or ≥25 with comorbidities, documented before prescribing
• Physical exam: Required before initiating treatment (can be done via telehealth if thorough, or delegated to an APRN/PA)
• Informed consent: Written consent is mandatory, and patients must receive the state’s ‘Weight-Loss Consumer Bill of Rights’ brochure
• Follow-up visits: At least every 3 months for anyone on obesity medications — miss this and you’re violating state law
• PDMP checks: Required before each controlled substance prescription (like phentermine)

Telehealth restriction: Florida prohibits prescribing controlled substances via telehealth for weight loss. The state’s telemedicine law allows remote controlled substance prescribing only for psychiatric treatment, addiction medicine, or emergency situations. Weight loss isn’t listed. That means you cannot prescribe phentermine via telehealth to Florida patients — but you can prescribe non-controlled GLP-1s remotely.

Texas: Collaborative Agreements Required for NPs

Texas mandates physician oversight for all NP prescribing:

• Prescriptive Authority Agreement: Must detail what medications NPs can prescribe, communication protocols, and quality assurance measures
• Monthly meetings: NPs and supervising physicians must have documented monthly quality review meetings
• Ratios: One physician can supervise up to 7 NPs/PAs in non-hospital settings
• Telehealth allowed: Texas permits telehealth prescribing (including controlled substances) if standard of care is met. PMP checks required for controlled drugs

California: Independence Coming, Corporate Practice Barriers

California is phasing in NP independence through AB 890:

• Current (2024-2025): NPs need physician-approved ‘standardized procedures’ to prescribe
• January 1, 2026: Qualified ‘104’ NPs (after 3 years/4,600 hours supervised practice) can practice independently
• Corporate Practice of Medicine: Even independent NPs cannot own medical practices in California — only physicians can. Weight-loss practices need physician ownership or MSO structures

Psychiatrists have full authority in California, but the state’s CPOM doctrine means telehealth companies operating here typically require physician-led models regardless of NP autonomy.

New York: Path to Independence After 3,600 Hours

New York allows NPs to practice independently after 3,600 hours (roughly 2 years) of practice under a collaborative agreement. After that, no physician oversight is required for prescribing weight-loss medications.

No special obesity rules at the state level, but the standard of care applies. The state requires checking the I-STOP prescription monitoring program before prescribing any Schedule II-IV controlled substances (including phentermine).

Telehealth parity: New York requires commercial insurers to reimburse telehealth visits at the same rate as in-person visits — good news for telehealth providers.

Pennsylvania: Collaborative Practice Required

Pennsylvania requires all NPs to have a Collaboration Agreement with a physician. Key details:

• Physician doesn’t need to be on-site but must review charts and be available for consultation
• Prescription blanks must include both the NP’s and collaborating physician’s names
• One physician can collaborate with up to four NPs
• No FPA legislation has passed yet (though bills have been introduced repeatedly)

Illinois: Full Practice Authority Available

Illinois allows experienced NPs to obtain Full Practice Authority after meeting criteria:

• ≥4,000 hours of clinical experience
• ≥250 hours of continuing education
• Filed application with the state

Major advantage: Illinois Medicaid reimburses APRNs at 100% of physician rates — unlike most states where NPs get 85-90%. This makes Illinois financially attractive for NP-led telehealth practices.

APRNs with FPA can prescribe controlled substances independently (with some limitations on Schedule II for the first year).

Telehealth Prescribing: Federal Flexibility, State Restrictions

Here’s where it gets tricky.

Federally, the DEA extended COVID-era telehealth flexibilities through December 31, 2025, allowing providers to prescribe controlled substances (like phentermine) via telehealth without an initial in-person exam. This has been extended multiple times and will likely continue into 2026.

But federal law doesn’t override state law. Several states have erected their own barriers:

• Florida: No controlled substance prescribing via telehealth for weight loss (psychiatric treatment is an exception, but that’s a gray area)
• Alabama: Requires an initial in-person exam before prescribing any controlled substance
• Idaho, South Carolina: Similar restrictions on remote controlled substance prescribing

GLP-1 agonists (non-controlled) can be prescribed via telehealth in all states, as long as you meet standard-of-care requirements:

• Establish a valid provider-patient relationship (usually requires live video consultation)
• Document thorough history and exam elements (vitals, weight, labs as needed)
• Provide informed consent and follow-up monitoring
• Check state-specific requirements (BMI documentation, counseling mandates, etc.)

Practical tip: Even if your state allows asynchronous prescribing (questionnaire-only), don’t do it for weight-loss medications. A Mississippi doctor had his license suspended in 2023 for prescribing Ozempic through instant messaging without audio/video. At minimum, conduct a video visit for initial evaluations.

The Economics: Can You Make This Work?

Let’s talk money.

Insurance Coverage Is Expanding

For years, weight-loss medications were mostly cash-pay. That’s changing fast:

• Medicare: In late 2024, the Biden administration proposed covering anti-obesity medications. By 2026, Medicare Part D plans are expected to include drugs like Wegovy and Mounjaro for eligible beneficiaries — a massive shift affecting millions of seniors
• Medicaid: Coverage varies by state, but expansion is underway as federal policy shifts
• Commercial Insurance: Most major insurers now cover GLP-1 weight-loss drugs with prior authorization. Typical requirements: BMI ≥30 (or ≥27 with comorbidities), documentation of lifestyle interventions, comprehensive treatment plan

Prior authorizations are the norm. Insurers want to see you’re managing the patient holistically — not just writing scripts. Document BMI, comorbidities, diet/exercise counseling, and follow-up plans in your notes.

Reimbursement for Visits

Psychiatrists can bill standard E/M codes (99213-99215) for weight management visits. If you’re combining weight management with psychiatric medication management, document both problems and code for total complexity.

Typical reimbursement:

• Initial psychiatric evaluation with med management (90792): ~$200 (Medicare)
• Follow-up med check (99213): ~$75-100
• Higher complexity visits (99214): ~$120-150

Telehealth parity laws in California, New York, Illinois, and Pennsylvania ensure remote visits are reimbursed at the same rate as in-person visits. Medicare has also maintained telehealth payment parity for mental health services and will likely continue through 2026.

MD vs. NP Reimbursement:

• Psychiatrists (MDs): 100% of physician fee schedule
• PMHNPs: Typically 85% of physician rates for Medicare (some private insurers pay 90-100%)
• Exception: Illinois Medicaid pays NPs at 100% of physician rates

The Platform Model: Economics Without Marketing Risk

Here’s the reality most providers don’t want to admit: acquiring patients for weight-loss services is expensive and time-consuming if you’re doing it yourself.

DIY marketing routes (SEO, Google Ads, directory listings) have real costs:

• SEO takes 6-12 months of consistent investment before generating meaningful patient flow
• Google Ads for mental health/weight loss keywords: $15-40+ per click; most clicks don’t convert to booked patients. Realistic cost per booked patient: $200-400+
• Directory listings (Psychology Today, Zocdoc) charge monthly fees (Zocdoc charges $35-100+ per booking) and you’re competing with hundreds of other providers on the same page
• Total monthly marketing spend for solo providers: $3,000-5,000+ with uncertain results

Even if you eventually build a profitable marketing funnel, there’s significant upfront risk and months of negative ROI while you test, optimize, and build momentum.

The alternative: Platforms like Klarity Health use a pay-per-appointment model. Instead of spending thousands monthly on marketing with uncertain results, you pay a standard listing fee per new patient lead who actually books with you. The value proposition is simple:

• No upfront marketing spend or monthly subscription fees
• Pre-qualified patients already matched to your specialty and availability
• No wasted ad spend on clicks that don’t convert
• Built-in telehealth infrastructure (no separate platform costs)
• Both insurance and cash-pay patient flow
• You control your schedule — only pay when you see patients

This is guaranteed ROI versus gambling on marketing channels. For providers starting out or scaling, it removes financial risk entirely.

Safety Considerations: The Mental Health Connection

One concern psychiatrists raise: ‘Are GLP-1s safe for my patients with mental health conditions?’

The evidence is reassuring. A 2025 meta-analysis in JAMA Psychiatry found no increase in depression or suicidality with GLP-1 medications versus placebo. Regulatory agencies (FDA, EMA) reviewed the data and found no causal link between GLP-1s and suicidal behavior.

In fact, some studies suggest improved mood and quality of life independent of weight loss. The biological rationale is being studied — GLP-1s reduce systemic inflammation and may influence brain regions involved in mood and reward.

Monitor appropriately:

• Screen for eating disorders before prescribing (some states like New Jersey require this)
• Document any baseline psychiatric conditions
• Schedule regular follow-ups to monitor both mental health and weight outcomes
• Be aware of GI side effects (nausea, vomiting) that could be confused with or exacerbate anxiety

Key point: With proper monitoring, psychiatrists can confidently add GLP-1s to their treatment approach. Many find that addressing obesity improves their patients’ overall mental health trajectory.

How to Stay Compliant: Practical Checklist

Here’s your compliance checklist for prescribing weight-loss medications:

Before Prescribing

• [ ] Verify your state’s scope-of-practice requirements (independent vs. collaborative)
• [ ] If NP in restricted state, establish written Prescriptive Authority Agreement
• [ ] Ensure you’re licensed in the state where the patient is located
• [ ] Register for state Prescription Drug Monitoring Program
• [ ] Review state-specific obesity treatment requirements

Patient Evaluation

• [ ] Conduct live video visit (minimum standard)
• [ ] Document BMI calculation (≥30, or ≥27 with comorbidities for most states)
• [ ] Take comprehensive history (weight history, previous attempts, medical conditions)
• [ ] Document physical exam elements (weight, BP, cardiac review)
• [ ] Order appropriate labs if needed (TSH, glucose, lipids to rule out secondary causes)
• [ ] Screen for contraindications (pregnancy, certain GI conditions, eating disorders)

Prescribing

• [ ] Check PDMP for controlled substances (phentermine, etc.)
• [ ] Obtain informed consent (written in states like Florida)
• [ ] Provide patient education materials (state-specific brochures if required)
• [ ] Document rationale for medication choice
• [ ] Provide nutrition/exercise counseling or referrals
• [ ] For GLP-1s: Verify insurance coverage, submit prior authorization if required

Follow-Up

• [ ] Schedule follow-ups per state requirements (every 3 months for Florida, etc.)
• [ ] Monitor weight, vital signs, side effects at each visit
• [ ] Document progress and treatment adjustments
• [ ] Re-check PDMP for ongoing controlled substance prescriptions
• [ ] Coordinate with primary care provider (best practice)

The Bottom Line: Should You Add Weight Loss to Your Practice?

Here’s the honest answer: It depends on your patient population, your interests, and your state’s regulatory environment.

You should consider it if:

• You’re already managing patients with medication-induced weight gain or metabolic syndrome
• Your state allows reasonable prescribing (either independent or affordable collaboration)
• You’re willing to invest in additional training (even just 20-30 hours of obesity medicine CME)
• You want to offer more integrated, holistic care
• You’re on a telehealth platform that handles patient acquisition and infrastructure

Skip it if:

• You’re in a state with severe restrictions (Florida’s controlled substance ban via telehealth, Alabama’s strict supervision)
• You don’t want to navigate complex prior authorizations
• Your collaborative physician costs are prohibitively high (NPs in restricted states)
• You’d rather focus exclusively on psychiatric medications

For most psychiatrists and PMHNPs on telehealth platforms, weight management represents a legitimate clinical expansion — not ‘scope creep,’ but comprehensive patient care. The medications work. The reimbursement is improving. And the patient need is massive (42% of U.S. adults have obesity).

The key is doing it right: staying within your competency, following state regulations, and documenting appropriately. If you’re uncertain, start with patients you already know, consider pursuing ABOM certification, and consult with colleagues who have experience in obesity medicine.

Ready to expand your practice without the marketing risk? Platforms like Klarity Health handle patient acquisition, credentialing, and infrastructure — letting you focus on clinical care while only paying for patients you actually see. No upfront marketing gamble. No wasted ad spend. Just qualified patients who need your expertise.

The weight-loss medication landscape is evolving fast. Psychiatrists and PMHNPs who adapt now — with the right training, compliance knowledge, and practice model — will be positioned to serve their patients better while building sustainable, diversified practices.

Frequently Asked Questions

Can psychiatrists legally prescribe weight-loss medications?

Yes. Psychiatrists (MD/DO) have full prescriptive authority in all 50 states for FDA-approved weight-loss medications, including GLP-1 agonists and controlled substances like phentermine. The key is practicing within your competency and following state-specific clinical guidelines.

Do I need special certification to prescribe GLP-1s?

No special certification is legally required, but additional training is recommended. Psychiatrists can pursue American Board of Obesity Medicine (ABOM) certification, which involves ~60 hours of obesity-related CME and passing a board exam. This strengthens your scope legitimacy and clinical competence.

Can PMHNPs prescribe weight-loss medications independently?

It depends on your state. In ~24 full-practice-authority states (Washington, Oregon, Colorado, etc.), experienced PMHNPs can prescribe independently. In reduced-practice states (New York, Illinois), you can gain independence after meeting hour/CE requirements. In restricted states (Texas, Florida, Alabama), you must have physician oversight via collaborative agreements.

Which states prohibit telehealth prescribing of controlled substances for weight loss?

Florida explicitly prohibits prescribing controlled substances (like phentermine) via telehealth for weight loss — psychiatric treatment is an exception. Alabama requires an initial in-person exam for all controlled substances. Idaho and South Carolina have similar restrictions. Always check your state’s current rules and verify federal DEA waivers are still in effect.

Can I prescribe weight-loss medications via telehealth in 2026?

Yes, for non-controlled medications (GLP-1 agonists like Wegovy, semaglutide). For controlled substances (phentermine), it depends on federal DEA waivers (currently extended through December 31, 2025, likely to continue) AND your state law. States like Florida prohibit it; most other states allow it. Always conduct at least a live video consultation before prescribing.

What are the documentation requirements for prescribing weight-loss drugs?

Core requirements across most states: document BMI ≥30 (or ≥27 with comorbidities), comprehensive history and physical exam, informed consent, nutrition/exercise counseling plan, and regular follow-up schedule. Some states have specific rules — Florida requires written consent, a state brochure, and 3-month follow-ups. Always check your state’s medical board obesity treatment guidelines.

Will insurance cover GLP-1 medications for weight loss?

Increasingly, yes. Most major commercial insurers now cover FDA-approved GLP-1 weight-loss drugs (Wegovy, Saxenda) with prior authorization. Medicare is expected to begin coverage in 2026 after policy changes. Medicaid coverage varies by state. Prior auths typically require documented BMI criteria, previous lifestyle interventions, and comprehensive treatment plans.

How much do weight-loss medication management visits reimburse?

Medicare rates for psychiatrists: initial evaluation with med management (~$200), follow-up med checks ($75-150 depending on complexity). Telehealth visits in states with parity laws reimburse at the same rate as in-person. PMHNPs typically receive 85% of physician rates from Medicare, though Illinois Medicaid pays NPs at 100%.

Do I need a collaborative physician as a PMHNP to prescribe GLP-1s?

Only in states that require physician collaboration for all NP prescribing (Texas, Florida, Pennsylvania, etc.). In full-practice-authority states, experienced PMHNPs can prescribe independently. Even in FPA states, some insurance companies and pharmacies may request physician involvement for high-cost medications — this is a practical barrier, not a legal requirement.

What’s the difference between prescribing Ozempic vs. Wegovy for weight loss?

Wegovy (semaglutide 2.4mg) is FDA-approved for obesity treatment. Ozempic (semaglutide up to 2mg) is FDA-approved only for type 2 diabetes. Prescribing Ozempic off-label for weight loss is technically allowed but has drawn scrutiny — Mississippi banned it in 2023. Best practice: prescribe FDA-approved obesity medications (Wegovy, Saxenda, Mounjaro for obesity) to avoid regulatory issues.

Can I prescribe compounded semaglutide?

This is risky. The FDA allows compounding only during drug shortages and with pharmaceutical-grade ingredients from registered facilities. Several state boards (Alabama, Florida) have warned against using compounded semaglutide from non-FDA-registered sources. If prescribing compounded versions, ensure your pharmacy partner is fully compliant with FDA and state pharmacy board rules.

What’s the liability risk for psychiatrists prescribing weight-loss medications?

Standard medical liability applies. Key risk mitigation: practice within your competency (get additional training), follow state clinical guidelines, document thoroughly, monitor patients regularly, and coordinate with primary care. Consider obtaining ABOM certification to demonstrate specialized competence. Ensure your malpractice insurance covers weight management services (most do, but verify).

How do I handle prior authorizations for GLP-1s?

Be prepared to document: patient’s BMI, comorbid conditions (diabetes, hypertension, cardiovascular disease), previous weight loss attempts (diet, exercise, other medications), comprehensive treatment plan including lifestyle modifications, and medical necessity statement. Some insurers require 3-6 months of documented lifestyle intervention before approving. Many practices hire prior auth specialists to handle the paperwork.

Can I bill for weight management as a psychiatrist?

Yes. Use standard E/M codes (99213-99215) based on visit complexity. If combining weight management with psychiatric care, document both issues and code for total complexity. Some providers also use obesity counseling codes (G0447 for Medicare), though this is typically used by primary care. Time-based coding works well if most of the visit involves counseling about nutrition and lifestyle.

What training should I get before prescribing weight-loss medications?

Minimum: 10-20 hours of CME on obesity medicine, GLP-1 pharmacology, and nutrition. Ideal: pursue American Board of Obesity Medicine (ABOM) certification (requires 60+ hours of education and passing exam). Also consider state-specific training on clinical guidelines and prescribing rules. Many online courses and webinars are available through ABOM, psychiatric associations, and obesity medicine organizations.

References

1. MedicalDirector Co. (2025). How Much Does a Collaborative Physician Cost for Weight Loss, Telehealth, and Medspas? 2025 Definitive Guide. Retrieved from https://www.medicaldirectorco.com/collaborative-physician-cost-weight-loss-telehealth/

2. MedicalDirector Co. (2025). Florida Weight Loss Clinic and Telehealth Compliance Guide (2025). Retrieved from https://www.medicaldirectorco.com/florida-weight-loss-clinic-and-telehealth-compliance-guide-2025/

3. MedicalDirector Co. (2025). Texas Weight Loss Clinic & Telehealth Compliance Guide (2025). Retrieved from https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/

4. Florida Administrative Code Rule 64B15-14.004. Standards for Prescription of Obesity Drugs (Effective August 8, 2022). Retrieved from https://www.law.cornell.edu/regulations/florida/Fla-Admin-Code-Ann-R-64B15-14-004

5. Foley & Lardner LLP. (2023, July 24). A Changing Regulatory and Reimbursement Landscape for Weight-Loss Drugs. Mondaq. Retrieved from https://www.mondaq.com/unitedstates/healthcare/1447512/a-changing-regulatory-and-reimbursement-landscape-for-weight-loss-drugs

Source:

• https://www.medicaldirectorco.com/collaborative-physician-cost-weight-loss-telehealth/#:~:text=The%20answer%20is%20almost%20always,yes
• https://www.medicaldirectorco.com/collaborative-physician-cost-weight-loss-telehealth/#:~:text=Nurse%20Practitioners%20
• https://journals.lww.com/tnpj/fulltext/2024/01000/36thannualaprnlegislativeupdate__improving.6.aspx#:~:text=The%20Pennsylvania%20BON%20grants%20CRNPs%2C,more%20physicians%20to%20deliver%20healthcare
• https://journals.lww.com/tnpj/fulltext/2024/01000/36thannualaprnlegislativeupdate__improving.6.aspx#:~:text=The%20Illinois%20Department%20of%20Financial,collaborative%20agreement%20following%20a%20TTP
• https://rxagent.co/blog/telehealth-compliance-trap#:~:text=The%20DEA%20gave%20us%20the,evaluation%20at%20the%20federal%20level
• https://rxagent.co/blog/telehealth-compliance-trap#:~:text=Despite%20federal%20DEA%20waivers%20extending,traps%20for%20digital%20health%20providers
• https://rxagent.co/blog/telehealth-compliance-trap#:~:text=1.%20Florida%3A%20The%20%22No,for%20Stimulants
• https://www.mondaq.com/unitedstates/healthcare/1447512/a-changing-regulatory-and-reimbursement-landscape-for-weight-loss-drugs#:~:text=New%20Jersey%20law%20requires%20that,and%20identify%20the%20risks%20associated
• https://drlewis.com/glp-1-medications-psychiatry/#:~:text=You%20know%20these%20drugs,disorders%2C%20and%20possibly%20depression%20itself
• https://drlewis.com/glp-1-mental-health/#:~:text=Now%20let%E2%80%99s%20talk%20about%20potential,where%20things%20get%20really%20interesting